These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7298269)

  • 1. Tranylcypromine isomers in the treatment of Parkinson's disease. Biochemical effects.
    Reynolds GP; Riederer P
    Int Pharmacopsychiatry; 1981; 16(1):30-3. PubMed ID: 7298269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tranylcypromine isomers and Parkinson's disease: new aspects of an old drug.
    Reynolds GP; Riederer P; Sandler M
    J R Soc Med; 1981 Sep; 74(9):649-52. PubMed ID: 7288807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tranylcypromine isomers in Parkinson's disease. Effect of low doses on monoamine oxidase inhibition and blood pressure response.
    Riederer P; Reynolds GP; Jellinger K; Seemann D; Danielczyk W
    Mod Probl Pharmacopsychiatry; 1983; 19():154-61. PubMed ID: 6865963
    [No Abstract]   [Full Text] [Related]  

  • 4. Platelet monoamine oxidase inhibition by deprenyl and tranylcypromine: implications for clinical use.
    Simpson GM; Frederickson E; Palmer R; Pi E; Sloane RB; White K
    Biol Psychiatry; 1985 Jun; 20(6):684-7. PubMed ID: 3922441
    [No Abstract]   [Full Text] [Related]  

  • 5. Tranylcypromine ('Parnate') overdose: measurement of tranylcypromine concentrations and MAO inhibitory activity and identification of amphetamines in plasma.
    Youdim MB; Aronson JK; Blau K; Green AR; Grahame-Smith DG
    Psychol Med; 1979 May; 9(2):377-82. PubMed ID: 472083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MAO inhibition as antidepressive mechanism reevaluated. A controlled study with tranylcypromine isomers.
    Beckmann H; Moises HW
    Mod Probl Pharmacopsychiatry; 1983; 19():211-4. PubMed ID: 6865965
    [No Abstract]   [Full Text] [Related]  

  • 7. Critical evaluation of measurement of platelet monoamine oxidase in man.
    Honecker H; Christ W; Müller-Oerlinghausen B; Coper H
    J Clin Chem Clin Biochem; 1976 Sep; 14(9):453-8. PubMed ID: 965902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet monoamine oxidase B activity in Parkinson's disease: a re-evaluation.
    Jarman J; Glover V; Sandler M; Turjanski N; Stern G
    J Neural Transm Park Dis Dement Sect; 1993; 5(1):1-4. PubMed ID: 8439389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidepressant efficacy of tranylcypromine isomers: a controlled study.
    Moises HW; Beckmann H
    J Neural Transm; 1981; 50(2-4):185-92. PubMed ID: 7017068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of tranylcypromine stereoisomers on monamine oxidation in man.
    Reynolds GP; Rausch WD; Riederer P
    Br J Clin Pharmacol; 1980 May; 9(5):521-3. PubMed ID: 7397067
    [No Abstract]   [Full Text] [Related]  

  • 11. Some properties of human platelet monoamine oxidase in iron-deficiency anaemia.
    Youdim MB; Grahame-Smith DG; Woods HF
    Clin Sci Mol Med; 1976 Jun; 50(6):479-85. PubMed ID: 6185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of tranylcypromine stereoisomers on depressive syndromes.
    Rüther E; Jungkunz G; Greil W; Zimmer R
    Mod Probl Pharmacopsychiatry; 1983; 19():203-10. PubMed ID: 6865964
    [No Abstract]   [Full Text] [Related]  

  • 13. Experience with tranylcypromine in early Parkinson's disease.
    Fahn S; Chouinard S
    J Neural Transm Suppl; 1998; 52():49-61. PubMed ID: 9564607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Determination and comparison of the plasma and urine concentrations in men given tranylcypromine stereoisomers].
    Lang A; Geissler HE; Mutschler E
    Arzneimittelforschung; 1979; 29(1):154-7. PubMed ID: 582109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose regimen of deprenyl (selegiline) and platelet MAO activities.
    Oreland L; Johansson F; Ekstedt J
    Acta Neurol Scand Suppl; 1983; 95():87-9. PubMed ID: 6428150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet monoamine oxidase B and plasma beta-phenylethylamine in Parkinson's disease.
    Zhou G; Miura Y; Shoji H; Yamada S; Matsuishi T
    J Neurol Neurosurg Psychiatry; 2001 Feb; 70(2):229-31. PubMed ID: 11160474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination treatment with selective monoamine oxidase inhibitors and dopaminergic agonists in Parkinson's disease: biochemical and clinical observations.
    Riederer P; Jellinger K; Danielczyk W; Seemann D; Ulm G; Reynolds GP; Birkmayer W; Koppel H
    Adv Neurol; 1983; 37():159-76. PubMed ID: 6407285
    [No Abstract]   [Full Text] [Related]  

  • 18. Relationship between tranylcypromine sulfate dose and monoamine oxidase inhibition.
    Grasso RA; Perry PJ; Sherman AD
    DICP; 1991 Jan; 25(1):99-100. PubMed ID: 2008794
    [No Abstract]   [Full Text] [Related]  

  • 19. I2-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson's disease.
    Gargalidis-Moudanos C; Pizzinat N; Javoy-Agid F; Remaury A; Parini A
    Neurochem Int; 1997 Jan; 30(1):31-6. PubMed ID: 9116585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoamine oxidase, phenylethylamine, norepinephrine and schizophrenia.
    Wyatt RJ; Karoum F; Stoff DM; Kleinman JE; Gillin JC; Jeste DV; Potkin SG
    Clin Genet; 1981 May; 19(5):437-42. PubMed ID: 7296934
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.